Phase Forward Enters Into Multi-Year Agreement With Quotient

Phase Forward has entered into a multi-year agreement with Quotient Clinical, a strategic business unit of Quotient Bioresearch (Quotient). Quotient is implementing Phase Forward’s InForm Global Trial Management (GTM) electronic data capture (EDC) solution to support data collection, management and analysis for its clinical trials.

In addition, the company is expected to use Phase Forward’s central designer module to enhance eCRF design efficiency and improve workflow in the study development process for EDC trials.

Quotient is implementing Phase Forward’s InForm Global Trial Management (GTM) electronic data capture (EDC) solution to support data collection, management and analysis for its clinical trials. In addition, the company will use Phase Forward’s Central Designer module to enhance eCRF design efficiency and improve workflow in the study development process for EDC trials.

The company said that by supporting faster accessibility and greater visibility into trial data, the EDC implementation will help Quotient to expand its full-service, in-house Biometrics offering. Moreover, Quotient plans to offer customers on-line access to trial data, making it easier for them to track progress to date or to review summary reports.

David Chalmers, vice president of biometrics at Quotient, said: “As an innovative provider of early drug development services, we want to ensure that our customers can take advantage of the benefits inherent in using EDC in Phase I trials, including access to high quality data within hours of collection, streamlined process efficiencies and rapid qualification of data. We selected InForm because of Phase Forward’s strong position in the marketplace and the company’s experience with Phase I trials.”